Fibrogen announces outcome of fda advisory committee review of roxadustat for treatment of anemia of chronic kidney disease

San francisco, july 15, 2021 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced that the u.s. food and drug administration (fda) cardiovascular and renal drugs advisory committee (crdac) voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (hif-ph) inhibitor, for the treatment of anemia due to chronic kidney disease (ckd) in adult patients. the committee based its recommendation on data from a global phase 3 program encompassing more than 8,000 patients. while the fda is not required to follow the committee's vote, the agency considers the committee's non-binding recommendations when making its decision.
FGEN Ratings Summary
FGEN Quant Ranking